CN102391389B - 一种胶体果胶铋化合物和其药物组合物及制备方法和应用 - Google Patents
一种胶体果胶铋化合物和其药物组合物及制备方法和应用 Download PDFInfo
- Publication number
- CN102391389B CN102391389B CN 201110230600 CN201110230600A CN102391389B CN 102391389 B CN102391389 B CN 102391389B CN 201110230600 CN201110230600 CN 201110230600 CN 201110230600 A CN201110230600 A CN 201110230600A CN 102391389 B CN102391389 B CN 102391389B
- Authority
- CN
- China
- Prior art keywords
- pectin
- compound
- bismuth
- colloid
- bismuth compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000001814 pectin Substances 0.000 title claims abstract description 83
- 229920001277 pectin Polymers 0.000 title claims abstract description 83
- 235000010987 pectin Nutrition 0.000 title claims abstract description 83
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 30
- 229910052797 bismuth Inorganic materials 0.000 title abstract description 21
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 title abstract description 21
- 239000012634 fragment Substances 0.000 claims abstract description 12
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 9
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims abstract description 9
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims abstract description 9
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 9
- GPKZHPOEAWCHQW-RMTXHFLUSA-N [Bi].O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)O Chemical compound [Bi].O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)O GPKZHPOEAWCHQW-RMTXHFLUSA-N 0.000 claims abstract description 7
- 230000002496 gastric effect Effects 0.000 claims abstract description 6
- YFBIYHPHTVAZCB-RMTXHFLUSA-N [K].O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)O Chemical compound [K].O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(=O)O YFBIYHPHTVAZCB-RMTXHFLUSA-N 0.000 claims abstract description 5
- 230000004054 inflammatory process Effects 0.000 claims abstract description 5
- 208000007107 Stomach Ulcer Diseases 0.000 claims abstract description 4
- UNSKAUSCLTVFGO-KCDKBNATSA-N methyl (2s,3r,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoate Chemical compound COC(=O)[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)C=O UNSKAUSCLTVFGO-KCDKBNATSA-N 0.000 claims abstract description 4
- 208000004300 Atrophic Gastritis Diseases 0.000 claims abstract description 3
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 3
- 208000036495 Gastritis atrophic Diseases 0.000 claims abstract description 3
- 208000032843 Hemorrhage Diseases 0.000 claims abstract description 3
- 208000015864 chronic erosive gastritis Diseases 0.000 claims abstract description 3
- 208000000718 duodenal ulcer Diseases 0.000 claims abstract description 3
- 239000000084 colloidal system Substances 0.000 claims description 35
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 27
- 229910052700 potassium Inorganic materials 0.000 claims description 27
- 239000011591 potassium Substances 0.000 claims description 27
- 239000002253 acid Substances 0.000 claims description 25
- 150000001622 bismuth compounds Chemical class 0.000 claims description 25
- 239000004568 cement Substances 0.000 claims description 25
- 239000000843 powder Substances 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 238000003756 stirring Methods 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 16
- 239000008187 granular material Substances 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 12
- -1 filter Substances 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 241001672694 Citrus reticulata Species 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 229920002521 macromolecule Polymers 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 238000007254 oxidation reaction Methods 0.000 claims description 4
- 238000007670 refining Methods 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 3
- 229910001451 bismuth ion Inorganic materials 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 230000002147 killing effect Effects 0.000 claims description 3
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 206010000087 Abdominal pain upper Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 208000019790 abdominal distention Diseases 0.000 claims description 2
- 238000004364 calculation method Methods 0.000 claims description 2
- 239000003616 gastrointestinal mucosa protective agent Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 230000036269 ulceration Effects 0.000 claims description 2
- 239000005995 Aluminium silicate Substances 0.000 claims 1
- 235000012211 aluminium silicate Nutrition 0.000 claims 1
- 239000012043 crude product Substances 0.000 claims 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims 1
- 229960000829 kaolin Drugs 0.000 claims 1
- 238000002386 leaching Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 abstract description 7
- 150000003839 salts Chemical class 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 229940126409 proton pump inhibitor Drugs 0.000 abstract description 3
- 239000000612 proton pump inhibitor Substances 0.000 abstract description 3
- YPQJHZKJHIBJAP-UHFFFAOYSA-N [K].[Bi] Chemical compound [K].[Bi] YPQJHZKJHIBJAP-UHFFFAOYSA-N 0.000 abstract description 2
- 150000001621 bismuth Chemical class 0.000 abstract description 2
- 201000005917 gastric ulcer Diseases 0.000 abstract description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract description 2
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 206010000060 Abdominal distension Diseases 0.000 abstract 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 abstract 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 6
- 150000007942 carboxylates Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 238000001246 colloidal dispersion Methods 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 description 1
- 102100036402 DAP3-binding cell death enhancer 1 Human genes 0.000 description 1
- 108010001394 Disaccharidases Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 101000929221 Homo sapiens DAP3-binding cell death enhancer 1 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920000715 Mucilage Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 210000002659 acromion Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229950002342 bisfentidine Drugs 0.000 description 1
- 229940104825 bismuth aluminate Drugs 0.000 description 1
- 229940097201 bismuth subcitrate potassium Drugs 0.000 description 1
- 229960001482 bismuth subnitrate Drugs 0.000 description 1
- ZQUAVILLCXTKTF-UHFFFAOYSA-H bismuth;tripotassium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [K+].[K+].[K+].[Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZQUAVILLCXTKTF-UHFFFAOYSA-H 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- RXPAJWPEYBDXOG-UHFFFAOYSA-N hydron;methyl 4-methoxypyridine-2-carboxylate;chloride Chemical compound Cl.COC(=O)C1=CC(OC)=CC=N1 RXPAJWPEYBDXOG-UHFFFAOYSA-N 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- FXJAOWANXXJWGJ-UHFFFAOYSA-N n-[4-(2-methyl-1h-imidazol-5-yl)phenyl]-n'-propan-2-ylmethanimidamide Chemical compound C1=CC(NC=NC(C)C)=CC=C1C1=CN=C(C)N1 FXJAOWANXXJWGJ-UHFFFAOYSA-N 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical compound O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110230600 CN102391389B (zh) | 2011-08-12 | 2011-08-12 | 一种胶体果胶铋化合物和其药物组合物及制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110230600 CN102391389B (zh) | 2011-08-12 | 2011-08-12 | 一种胶体果胶铋化合物和其药物组合物及制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102391389A CN102391389A (zh) | 2012-03-28 |
CN102391389B true CN102391389B (zh) | 2013-06-12 |
Family
ID=45858789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110230600 Active CN102391389B (zh) | 2011-08-12 | 2011-08-12 | 一种胶体果胶铋化合物和其药物组合物及制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102391389B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018524558A (ja) * | 2015-06-23 | 2018-08-30 | 山西振東安特生物製薬有限公司Shanxi Zhendong Ante Biopharmaceutical Co.,Ltd. | コロイドペクチンビスマス含有製剤の溶出性の検出方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103142637A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 一种包含胶体果胶铋的胶囊 |
CN103142548B (zh) * | 2013-03-21 | 2014-07-23 | 青岛正大海尔制药有限公司 | 胶体果胶铋胶囊 |
CN105461823B (zh) * | 2015-04-07 | 2018-04-06 | 湖南华纳大药厂股份有限公司 | 一种胶体果胶铋的制备方法及其药物组合物黏附性的控制方法 |
CN104880428B (zh) * | 2015-06-23 | 2016-07-06 | 山西振东安特生物制药有限公司 | 一种胶体果胶铋或含胶体果胶铋制剂中铋含量的测定方法 |
CN107118285A (zh) * | 2015-12-14 | 2017-09-01 | 于学敏 | 高纯度胶体果胶铋化合物及结构式、分子式、分子量的确证 |
CN111217937B (zh) * | 2020-03-25 | 2022-04-22 | 山西振东安特生物制药有限公司 | 一种制备胶体果胶铋的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1088437A (zh) * | 1992-12-23 | 1994-06-29 | 大同市药物研究所 | 胶态果胶铋药物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200715961A (en) * | 2005-10-28 | 2007-05-01 | Sinon Corp | Herbicide composition |
-
2011
- 2011-08-12 CN CN 201110230600 patent/CN102391389B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1088437A (zh) * | 1992-12-23 | 1994-06-29 | 大同市药物研究所 | 胶态果胶铋药物 |
Non-Patent Citations (6)
Title |
---|
Colloidal Bismuth Pectin: An Alternative to Bismuth Subcitrate for the Treatment of Helicobacter pylori– Positive Duodenal Ulcer;Yuqiang Nie et al.;《Helicobacter》;20011224;第4卷(第2期);128–134 * |
Yuqiang Nie et al..Colloidal Bismuth Pectin: An Alternative to Bismuth Subcitrate for the Treatment of Helicobacter pylori– Positive Duodenal Ulcer.《Helicobacter》.2001,第4卷(第2期),128–134. |
含铋III配合物的合成及铋的配位性质;蒋琪英等;《化学进展》;20061231;第18卷(第12期);1634-1643 * |
温钦海等.胶体果胶铋原料药的稳定性实验研究.《中国当代医药》.2010,第17卷(第9期), |
胶体果胶铋原料药的稳定性实验研究;温钦海等;《中国当代医药》;20100930;第17卷(第9期);18、21 * |
蒋琪英等.含铋III配合物的合成及铋的配位性质.《化学进展》.2006,第18卷(第12期), |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018524558A (ja) * | 2015-06-23 | 2018-08-30 | 山西振東安特生物製薬有限公司Shanxi Zhendong Ante Biopharmaceutical Co.,Ltd. | コロイドペクチンビスマス含有製剤の溶出性の検出方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102391389A (zh) | 2012-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102391389B (zh) | 一种胶体果胶铋化合物和其药物组合物及制备方法和应用 | |
Nayak et al. | Trigonella foenum-graecum L. seed mucilage-gellan mucoadhesive beads for controlled release of metformin HCl | |
CN104127761A (zh) | 一种小儿健胃消食软体制剂及其制备方法 | |
CN104146197A (zh) | 一种小儿健胃消食果冻粉及其制备方法 | |
CN103251648B (zh) | 治疗血磷酸盐过多症及缺铁性贫血症的铁基蒙脱石药物及其制备方法 | |
CN101019984B (zh) | 一种治疗便秘的中药制剂 | |
CN105030689A (zh) | 盐酸小檗碱掩味微丸及其制剂 | |
CN108057028A (zh) | 片剂形式的肠溶包衣的胃内滞留口服剂型及其应用和药物组合物 | |
TWI742004B (zh) | 矽酸鋯組合物的延伸用途與其使用方法 | |
CN103585164A (zh) | 一种溶出度增加的塞来昔布固体组合物及其制备方法和应用 | |
JP5327682B2 (ja) | 緩下剤として使用される医薬組成物 | |
CN111202781A (zh) | 一种和胃解毒胶囊在制备镇痛药物、促胃排空药物或促肠道运动药物方面的应用 | |
CN103948621B (zh) | 一种香菇多糖的口服剂型及其制备方法 | |
CN104367588B (zh) | 地塞米松果胶锌复合凝胶口服结肠定位释药微丸 | |
CN102151286B (zh) | 一种铝碳酸镁片及其制备方法 | |
CN103800290A (zh) | 盐酸氨基葡萄糖微丸制剂及其制备方法 | |
CN107118285A (zh) | 高纯度胶体果胶铋化合物及结构式、分子式、分子量的确证 | |
CN105461823B (zh) | 一种胶体果胶铋的制备方法及其药物组合物黏附性的控制方法 | |
CN102139016A (zh) | 一种用于治疗慢性胃炎的枸杞漂浮片及其制备方法 | |
CN103393751A (zh) | 一种止咳贴及其制备方法 | |
CN103070842A (zh) | 一种米格列醇缓释片的制备方法 | |
CN103784683A (zh) | 一种治疗肥胖症的中药组合物及其制备方法和应用 | |
JP6206420B2 (ja) | クエン酸第二鉄を高濃度で含有するゲル状組成物の製造方法 | |
Wang et al. | Coating carboxymethylpachymaran (CMP) on bovine serum albumin (BSA) nanoparticles for the encapsulation and oral delivery of curcumin | |
CN103550332A (zh) | 一种富含羟基酪醇、枸杞多糖和苹果多酚的用于保肝的胶囊和制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160901 Address after: 037006 -2, 2 dragon garden, Shanxi, Datong Patentee after: Datong microvascular and Microcirculation Research Institute Address before: 037008 Datong Drug Research Institute, 1 Zhenxing street, Shanxi, Datong Patentee before: Yu Xuemin |
|
DD01 | Delivery of document by public notice |
Addressee: Datong microvascular and Microcirculation Research Institute Document name: Notification of Passing Examination on Formalities |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170515 Address after: 037008 No.1, Zhenxing street, Shanxi, Datong Patentee after: Yu Xuemin Address before: 037006 -2, 2 dragon garden, Shanxi, Datong Patentee before: Datong microvascular and Microcirculation Research Institute |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Datong microvascular and Microcirculation Research Institute Document name: Notification of Passing Examination on Formalities |